XSHG
600080
Market cap255mUSD
Oct 09, Last price
4.63CNY
1D
1.09%
1Q
-2.94%
Jan 2017
-63.14%
Name
Ginwa Enterprise Group Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Ginwa Enterprise (Group) Inc. is a pharmaceutical company that specializes in the research, development, manufacturing, and commercialization of traditional Chinese, biological, and chemical medicines within China. The company's diverse product line encompasses treatments for a broad spectrum of medical conditions, including those related to orthopedics, immune system function, pediatric care, infectious diseases (such as antibiotics and antivirals), digestive health, gynecological issues, and cardiovascular ailments, as well as offerings for fever and pain relief. These medications are distributed in various common forms, specifically capsules, powders, and tablets. Ginwa Enterprise (Group) Inc. maintains its headquarters in Xi'an, China.
Key people
Shoufeng Zhang
Chief Financial Officer · since 2025
Mei Zhang
General Manager · since 2011
Xueyan Chen
Deputy General Manager
Zhuojun Han
Deputy General Manager · since 2025
Zhihua Shi
Deputy General Manager · since 2025
Yanping Song
Deputy General Manager
Yu Tao
Deputy General Manager · since 2011
Boyue Xing
Deputy General Manager, Director
Guangdong Zhao
Deputy General Manager · since 2025
Xiaoling Lu
Director · since 2006
Chuan Qin
Director · since 2011
Shengming Sun
Director
Qing Wan
Director · since 2022
Xing Wang
Director
Yajiang Xing
Chairman of the Board
Chaoyang Zhang
Secretary of the Board, Director · since 2025
Xiaojuan Liu
Independent Director · since 2023
Independent Director
Yajie Wu
Independent Director · since 2023
Ge Zhao
Independent Director · since 2022
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||